Keywords: lynx, solexa, acquire, dna, technology, assets, therapeutics

Lynx and Solexa acquire DNA technology assets

Article | 5 April 2004

• Print This

Lynx Therapeutics of the USA and UK-based Solexa have announced the joint acquisition from Switzerland-based Manteia SA of the rights to proprietary technology assets for DNA colony generation.

The acquired technology assets feature a process to enable parallel amplification of millions of DNA fragments, each from a single DNA molecule, to create DNA colonies or "clusters." The clusters are dense collections of DNA molecules on a surface, which should enable fast and simplified preparation of the biological sample for analysis and allow reduced reagent consumption as a result of the highly parallel nature of the analysis.

Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.

For Lynx, the planar cluster technology, when fully developed, will replace its Megaclone know-how, a process that transforms a sample containing millions of DNA molecules into one made up of millions of micro- beads coated with DNA. For Solexa, the DNA cluster technology will be combined with its novel base-at-a-time sequencing biochemistry to complement the systems already in development, based on single molecule arrays, for the comprehensive and economical analysis of individual genomes.